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The MRI community is using quantitative mapping techniques
to complement qualitative imaging. For quantitative imaging to
reach its full potential, it is necessary to analyze measure-
ments across systems and longitudinally. Clinical use of quan-
titative imaging can be facilitated through adoption and use of
a standard system phantom, a calibration/standard reference
object, to assess the performance of an MRI machine. The
International Society of Magnetic Resonance in Medicine
AdHoc Committee on Standards for Quantitative Magnetic
Resonance was established in February 2007 to facilitate the
expansion of MRI as a mainstream modality for multi-
institutional measurements, including, among other things,
multicenter trials. The goal of the Standards for Quantitative
Magnetic Resonance committee was to provide a framework
to ensure that quantitative measures derived from MR data
are comparable over time, between subjects, between sites,
and between vendors. This paper, written by members of the
Standards for Quantitative Magnetic Resonance committee,
reviews standardization attempts and then details the need,
requirements, and implementation plan for a standard system
phantom for quantitative MRI. In addition, application-specific
phantoms and implementation of quantitative MRI are
reviewed. Magn Reson Med 79:48–61, 2018. VC 2017 Inter-
national Society for Magnetic Resonance in Medicine.
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INTRODUCTION: NEED FOR QUANTITATIVE
PHANTOMS
Over the past two decades, interest in the use of MR bio-
logical markers (or “biomarkers”) to provide information
critical to the development of novel therapeutic agents
and improved clinical diagnostics has grown. Biomarkers
(1–3) are objectively measured parameters that indicate
the biological state, biological/pathobiological processes,
or pharmacologic responses to treatment. Examples of MR
biomarkers include tumor volume (4–6), brain volume
(7–10), functional network connectivity (11–13), isotropic
(14,15) or anisotropic (16,17) water diffusion constants
(18), local metabolite concentrations (10,15,19,20), blood
flow fields (21–23), fat fraction (24–27), lung function
(28,29), temperature (30–32), and tissue elasticity (33,34).
Medical imaging modalities are now expanding to
include quantitative mapping of biomarkers in addition
to qualitative imaging. Although quantitative mapping of
biomarkers can greatly increase the amount, reliability,
and comparability of the data obtained from medical
imaging, it requires careful standardization of protocols
and the development of phantoms (standard reference
objects or calibration structures) to validate the accuracy
of these in vivo measurements, and to assess the repeat-
ability and reproducibility of the measurements across
imaging platforms and time.
Despite substantial recent advances in biomedical sci-
ence, the process of developing more effective and safer
therapeutics for patients has become increasingly chal-
lenging and costly (35). Magnetic resonance biomarkers
are one potential way to address these problems, such as
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in clinical trials that evaluate novel therapeutic agents or
establish efficacy and/or safety for regulatory approval as
a substitute for a clinical characteristic reflecting patient
condition, function, or survival (i.e., surrogate endpoint).
The expectation is that information provided by bio-
markers will improve predictability and efficiency along
the path from laboratory concept to commercial product
(36). Another motivation for the implementation of
image-based biomarkers is their use in safe, noninvasive
diagnostics replacing biopsy-based diagnostics. Examples
include the use of MR elastography to diagnose and
stage liver cirrhosis and fibrosis (34,37) and dynamic
contrast MRI to measure key tissue parameters of tumors
(38) to assess the effectiveness of cancer treatment.
Finally, the development of accurate and sensitive MR-
based biomarkers may lead to physical diagnostics of
conditions such as mild traumatic brain injury and many
types of neural diseases for which there are no adequate
physical diagnostics and which rely on neuropsychologi-
cal assessment (17,39).
An important part of precision measurement of pri-
mary MR parameters is to develop rigorous definitions of
the measurands. For example, the static magnetic field,
B0, contains contributions from the scanner magnet and
from diamagnetic and/or paramagnetic components aris-
ing from the radiofrequency (RF) coil assembly and sam-
ple under study. Although these effects are relatively
small, the impact of their presence can be significant on
image quality and quantitative parameter accuracy and
precision. For high-performance quantitative imaging,
careful definitions and recommended procedures for
measuring such effects are required. Perhaps more
importantly, careful definitions of the proton spin relaxa-
tion times are required. Although exponential relaxation
of the proton magnetization is often observed, multi-
exponential or nonexponential relaxation can be present
in many materials, including biological tissue. Different
apparent relaxation times for complex materials are mea-
sured by different pulse sequences on different platforms
(e.g., NMR spectrometer systems versus MRI scanners).
Pragmatic definitions of apparent T1 and T2 relaxation
times are required if one desires to use relaxation times
as biomarkers of tissue type and disease processes.
The Radiological Society of North America (RSNA)
established the Quantitative Imaging Biomarkers Alli-
ance (QIBA) (40) to address this issue by developing
quantitative imaging protocols, phantoms, and technical
standards documents, referred to as profiles. In addition,
the National Cancer Institute established the Quantitative
Imaging Network (41) to help validate quantitative imag-
ing through the use of standard protocols and phantoms.
The December 2016 issue of Tomography—A Journal for
Imaging Research was devoted to the work of the Quanti-
tative Imaging Network, which is bringing quantitative
imaging methods into clinical utility, measuring response
to therapy, and supporting clinical decision making dur-
ing clinical trials (42). The development of a standard sys-
tem phantom by the Standards for Quantitative Magnetic
Resonance committee is meant to support these efforts by
establishing a procedure to develop MRI phantoms with
traceable, validated, and monitored components.
Biomarkers must provide quantitative measures of ana-
tomical, physiological, and/or biochemical characteristics
that are comparable over time, between subjects, between
scanner locations, between manufacturers, across protocols,
and across field strengths. Such comparisons can be diffi-
cult because of a variety of purely technical factors ranging
from subtle variations in hardware performance influenc-
ing the MR signal to differences in hardware and software
between and within manufacturers, differences in image
acquisition and reconstruction protocols, and differences
in data processing and analysis. As with any analytical
instrument, regular quality assurance of the MRI scanner
allows many of these factors to be characterized and, when
feasible, considered when extracting quantitative measure-
ments from the MR data. Existing phantoms are designed
for accreditation (see Supporting Information) or for mea-
surement of a single specific scanner property or for a spe-
cific application (see “Application of Specific Phantoms”
section). Few of the existing phantoms contain SI-traceable
components, few are monitored for long-term stability, and
few have been validated by a national metrology institute
(43,44). In this paper, we propose that a standard system
phantom, with stable and traceable properties enabling
evaluation of as many critical aspects of the MRI system as
possible, would facilitate the use of quantitative MRI meas-
urements as a biomarker.
SYSTEM PHANTOM DESIGN CONSIDERATIONS
Magnetic Resonance Quantities to Be Evaluated by the
System Phantom
The system phantom should be designed to assess basic
system parameters such as signal-to-noise ratio (SNR), res-
olution, relaxation times, proton density, and geometric
distortion, and to compare results across manufacturers,
hardware and software versions, time, and physiologic
ranges at 1.5 T and 3 T. A standard system phantom pack-
age requires, in addition to the physical phantom, stan-
dard imaging protocols, standard image analysis
procedures, a full description of the phantom including
field and temperature-dependent material properties,
numerical description of the phantom to allow simula-
tions, setup and imaging instructions, and a data archive
to allow comparison of data and scanner assessment.
The American College of Radiology (ACR) phantom,
described in the Supporting Information, was designed to
partially meet the goals of a system phantom, but it has cer-
tain limitations. For example, certain measurements (e.g.,
section thickness and high contrast resolution) can only be
obtained in one orientation. In addition, there is no orga-
nized long-term monitoring of the phantom components for
stability. Over time, it is known that the acrylic will warp,
which can render geometric components unusable (45).
Here we describe an MRI system phantom to meet the
aforementioned goals, which will contain SI-traceable
components, be monitored for long-term stability, and be
validated by a national metrology institute. The system
phantom can address several concerns with implementa-
tion of quantitative MRI, including system constancy and
assessment of the data acquisition and analysis pipeline.
The following quantities can affect the accuracy or pre-
cision of measurement in MRI studies, and are candidate
quantities to be evaluated by a system phantom. Some
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quantities such as B0, B1, and gradient nonuniformity are





1 ) nonuniformity is a major confounding
factor, especially with the use of high magnetic fields
and surface coils for transmission. The accuracy of the
flip angle achieved at any position depends on the Bþ1
inhomogeneity and can be determined by Bþ1 mapping
(46). For example, the Bþ1 map may be used during T1
mapping model fits to correct the desired versus
achieved flip angle (47).
B1 (Receive) Nonuniformity
With the increasing use of high channel count phased
array and anatomy-specific surface coils for MR signal
reception, B1 receive (B

1 ) inhomogeneity must be assessed
and addressed. Characterized by spatial variations in image
intensity and SNR, it confounds both the accuracy and
precision of many quantitative MRI applications if not pro-
spectively accounted for during parameter estimation. The
validity of the reciprocity principle that allows B1 receive
nonuniformity to be measured from transmit nonunifor-
mity (B1 map) has been challenged at very high field
strengths.
B0 Nonuniformity
Assuming good shimming, the main magnetic field, B0,
can generally be considered uniform over standard clini-
cal imaging fields of view (FOVs). However, for extended
FOVs (e.g., breast imaging), nontrivial deviations from
uniformity can occur in the periphery. Susceptibility
effects introduced by air–tissue interfaces or other non-
tissue materials (e.g., gadolinium contrast media) will
also induce local changes in the effective B0 field. For
certain applications, such as proton-density fat fraction
estimation, B0 inhomogeneity causes spatially dependent
phasing of chemical species signals, whereas for other
applications, such as echo-planar imaging–based diffu-
sion imaging, it can lead to geometric image distortion.
The effective B0 field can be mapped using multi-echo
procedures, or indirectly characterized using proxy mea-
sures like SNR and image uniformity.
Signal-to-Noise Ratio
The SNR is known to be influenced by several system
factors, such as resonance frequency, flip angle accuracy,
transmitter gain, coil loading (fill factor) and tuning,
scan parameters, slice profile and shape, scan accelera-
tion (e.g., use of parallel imaging), image reconstruction
method, postprocessing, and parameter fitting strategy.
Quantitative measurement of SNR can give a general
indication of the state of the imaging pipeline.
To measure SNR, a relatively large, uniform compart-
ment of a phantom filled with a solution that has well-
characterized, stable proton density and T1 and T2 relax-
ation times is recommended to properly follow the
National Electrical Manufacturers Association and Inter-
national Electrotechnical Commission (IEC) methods
(48,49). This allows for the use of one of the four proto-
cols described in the National Electrical Manufacturers
Association standard MS1-2008 (R2014) to determine
SNR (48). The first two protocols use image subtraction
from a pair of nominally identical images to determine
image noise; these methods are sensitive to system drift
artifacts and suggest that the images be obtained within
a minimum of elapsed time. The third protocol uses a
single k-space scan to produce two images, which are
subtracted; this method reduces the sensitivity to system
drift. The fourth protocol measures the noise on a zero-
signal region outside the phantom. It is imperative to ref-
erence the SNR measurement method used to assess the
data to allow comparisons. We do recognize that given
the multiple goals of the proposed system phantom, it is
space-limited, and therefore may not be able to include
large volumes recommended for SNR measurements.
Image Uniformity
Ideal homogenous signal across the FOV can be affected
by many factors, including, but not limited to, B0, B1
nonuniformities (transmit and receive), gradient linear-
ity, eddy currents, and postprocessing. Image uniformity
is also a general indicator of the performance of the
imaging pipeline.
For measuring image uniformity, National Electrical
Manufacturers Association methods in standard MS3-2008
(R2014) are recommended (50). The method recommends
a phantom that covers at least 85% of the specification
area. The proposed system phantom should cover at least
85% of most head coils. The method also recommends
that the fill solution have physiologic T1, T2, and spin den-
sity values. Multiple methods are outlined to calculate the
image uniformity and assess the image contrast.
Gradient Amplitude
Inaccuracies in gradient amplitude can affect measure-
ments of object size, which may be critical for studies
requiring accurate registration. This parameter can be
measured by comparing image measurements of phan-
toms with known properties.
Geometric Linearity
Geometric linearity can be affected either by B0 nonuni-
formity and/or gradient nonlinearity. Gradient nonlinear-
ity typically leads to geometric distortion and needs to
be measured in all three axes. These nonlinearities are
more pronounced at the edges of the FOV. Manufac-
turers apply at least a 2-dimensional gradient nonlinear-
ity correction before image display, but this correction
may not be sufficient for some applications (51) and can
degrade image resolution (52).
To assess the geometric accuracy for head size vol-
umes, the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) MagPhan phantom (The Phantom Laboratory,
Salem, New York, USA) can be used (53,54). Any phan-
tom design for such application must make it possible to
identify the phantom orientation from the image itself.
This requires that there is sufficient asymmetry in the
phantom or built-in fiduciary features to enable the
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orientation to be automatically determined. This can be
in conflict with the design of a geometric distortion
phantom, which requires a regular set of points. When
using the ADNI phantom, the ADNI software should be
used to assess the geometric distortions, to minimize any
measurement variance caused by the use of varying anal-
ysis software packages (54).
Slice Position and Profile
B0 variations, RF amplifier nonlinearities, and gradient
nonlinearity problems can affect slice position and pro-
file. Hence, accurate determination of the slice profile is
required in MRI. The B1 variation across the slice war-
rants accurate measurement of slice profile and slice
crosstalk effects. Accuracy of slice separation is a related
factor.
Contrast Compartments
Contrast response, such as T1, T2 and proton density
measurements, can be measured through any number of
experiments and signal models. Contrast compartments
allow testing of the entire measurement protocol, includ-
ing data acquisition and analysis. These components can
reveal issues from the scanner or acquisition and from
the processing pipeline, such as an incomplete signal
model.
The recommended system phantom should have three
groups of at least 10 compartments. Within each group, a
single parameter (proton density, T1, or T2) changes in a
manner that is as independent as possible with respect
to the other two parameters. Care must be taken to
ensure that all spheres required for geometric accuracy
assessment using automated analysis procedures have
appropriate signal characteristics on at least one specific
pulse sequence and set of acquisition parameters. If the
contrast compartments are temperature dependent, the
temperature dependence should be measured, and tem-
perature correction coefficients should be reported.
In the proton density group, at least 10 compartments
in which the proton density varies linearly over the
range of 50 to 100% relative to pure water is desired.
In the T1 relaxation time group, at least 10 compart-
ments in which the T1 relaxation time varies linearly
over the range of 100 to 2000 ms at 1.5 T is desired. The
T1 relaxation time values included should cover physio-
logic ranges at both 1.5 T and 3 T, including short relaxa-
tion times typically encountered intravascularly following
the administration of gadolinium contrast media.
In the T2 relaxation time group, at least 10 compart-
ments in which the T2 relaxation time varies linearly
over the range of 20 to 200 ms at 1.5 T is desired. The T2
relaxation time values included should cover physiologic
ranges at both 1.5 T and 3 T.
The software should be open source to allow users to
include their quantitative analysis for T1, T2, and proton
density measurements. Software that enables researchers
to use their own model for analysis encourages compari-
son of the acquisition and processing procedures for
relaxometry. The software should include models for the
recommended imaging protocol and allow for new relax-
ometry experiments and models.
High-Contrast Resolution
Point spread function, line spread function, or modula-
tion transfer function could provide quantitative mea-
sures of spatial resolution (49). These are in addition to
the “number of objects resolved” metric used to assess
the ACR phantom high-contrast resolution insert. (Cur-
rent ACR guidelines state “one visually determines the
number of individual small bright spots” (55,56).)
System Constancy
Scanner performance and stability should be tracked
over time for a range of the parameters described in this
section and others, such as transmitter and receiver gain,
receiver bandwidth, image ghosting (49), and eddy cur-
rents (57). Deviations in the system constancy measure-
ments detected using the system phantom can reveal
equipment failure or an underlying issue before it is
noticed in clinical imaging (45).
Specific Design Criteria
1. All components should be in the public domain,
including the phantom design, solid models, and
material properties.
2. The standard system phantom should allow charac-
terization of bias and variance of most of the desired
quantities listed in “Quantities to be Evaluated,”
with the caveat that no single phantom will be opti-
mal for all of the items listed.
3. No specific recommendation is provided with
respect to spherical versus cylindrical geometry.
Given the large variety of MR coils, including multi-
channel head coils, breast coils, and knee coils, a
system phantom design will never be suitable for
imaging in all current configurations.
4. All filling materials should be well-characterized
with respect to physical NMR properties and stabil-
ity. No user-fillable compartments should be
included to maintain consistent and traceable phan-
tom characteristics.
5. The phantom should be handled easily and posi-
tioned by MRI technologists. A positioning device
should be designed to allow the system phantom to
be accurately and precisely positioned at locations
off-isocenter, including the volume of a typical tho-
racic or abdominal cavity (z-direction) and coverage
of the shoulders and/or hips (x-direction). It is recog-
nized that this will require a manufacturer-specific
design component or will require that the site can
independently and reproducibly provide an appro-
priate surface upon which the proposed positioning
device can be placed.
6. The basic imaging protocol duration should be less
than 1 h. Although more in-depth imaging protocols
may be included, the general use of the phantom
will require fitting the image acquisitions into tight
schedules. There should be an automated analysis of
the measured data to encourage regular use of the
phantom for quality control purposes. The algo-
rithms must perform well over prescribed ranges of
SNR and artifact levels (e.g., geometric distortion, B1
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nonuniformity). The software should have well-
defined regions of interest to enable automated selec-
tion of signals of interest.
7. The system phantom should have cost commensu-
rate with existing phantoms. A complex, expensive
system phantom may have diminishing value.
8. The phantom should be easy and safe to ship (such
as if the phantom is dropped), and any hazardous
materials should be contained so that they would
not leak and require hazardous clean-up.
9. The phantom should be robust, with at least a 5-year
stability, ideally close to 10 years.
10. The phantom should have well-defined accuracy and
SI-traceability of important properties, such as
dimensional parameters and composition of contrast
compartments, such as using inductively coupled
plasma mass spectroscopy. A metrology institution
should be enlisted to verify accuracy and monitor
stability of the system phantom.
11. The design should allow for the development and
implementation of automated evaluation software
tools. For example, the orientation of the phantom
should be uniquely determined from the images; it
does not need to be known beforehand. Ideally, it
should be possible to analyze the images even if the
scans are partially truncated or incorrectly oriented
in the FOV, as human error will lead to such issues,
particularly in large multicenter trials.
12. The phantom should come with an open-source
analysis package to allow consistent analysis of
imaging data using common DICOM format. Alterna-
tive or more extensive analysis should be encouraged
by including all information required for analysis,
such as region of interest positions. The image analy-
sis software must be able to read images in the
DICOM file format and interpret information specific
to each manufacturer, even from private tags that are
sometimes required for analysis. The software should
be open source to allow users to test new algorithms
or fitting methods.
13. The phantom should come with required environ-
mental monitoring, such as a thermometer, to ade-
quately assess potential non-system/environment-
dependent effects (e.g., temperature).
14. The image analysis software should allow for
advanced/complete protocol analysis. The require-
ments may be different for a phantom used to detect
whether a system is within manufacturer specifica-
tions compared with a phantom used for measure-
ments to normalize or alter the actual data.
15. Certain features, such as the high-contrast resolution
inset, should be compatible with other imaging
modalities (e.g., CT, positron emission tomography,
ultrasound) to have a single standard, when possible.
CURRENT MRI STANDARDS, PHANTOMS, AND
QUANTIFICATION EFFORTS
Recognizing the need for standard phantoms, several
organizations/initiatives have developed MRI phantoms.
They include phantoms to (i) characterize the physical
performance of MRI systems for acceptance testing and
comparison of different commercial systems perfor-
mance, (ii) characterize time-related changes in the phys-
ical performance of imaging systems for specific clinical
protocols, and (iii) develop methods for accreditation of
MRI systems for clinical practice. We identified signifi-
cant efforts by the American Association of Physicists in
Medicine (58,59), European Communities Biomedical
Engineering Advisory Committee (60–62), Magnetic Res-
onance National Evaluation Team (63–67), and the ACR
(56,68,69), including the ACR MR Accreditation Phan-
tom (Supporting Fig. S1). Each of these efforts is briefly
reviewed in the Supporting Information.
APPLICATION OF SPECIFIC PHANTOMS
Application-specific phantoms are developed to evaluate
a specific biomarker or to enable quality assurance of a
measurement. Unlike phantoms used to characterize fun-
damental features of MRI systems, such as the proposed
system phantom, these phantoms focus on those parame-
ters that are specific to the target application. The purpose
of this section is to discuss the objective measurement, the
rationale for that measurement, and details of the phantom
design for each application. The discussion is limited to
phantoms whose descriptions have been disclosed in
either publications or publicly available abstracts and pro-
ceedings papers.
Structural Brain Imaging Phantom
The ADNI program for structural brain imaging created a
phantom that fits within many head coils and is scanned
immediately after each patient scan (54). This head-
volume phantom was used by three successful study
phases: ADNI1, ADNI Grand Opportunity (GO), and
ADNI2. The ADNI program has used the phantom to
assess more than 350 systems (70). The phantom is used
for measurements of SNR, contrast-to-noise ratio, and
geometric distortion. The measurements allow correction
of patient images with respect to tissue contrast and geo-
metric distortion, as needed for segmentation and for
volume measurements.
The ADNI multisite study found several scanner errors,
which may have been missed without central monitoring.
Errors including misidentification of gradient hardware,
disabling of autoshim, and miscalibrated laser alignment
light, if undetected would have contributed to imprecision
in quantitative metrics at more than a quarter of all ADNI
sites (54). In conclusion, the ADNI group’s suggestions for
best practices include minimizing large signal voids, using
a keyed geometry, enabling tight integration with the qual-
ity control process, using the phantom as part of site quali-
fication for inclusion in a clinical trial, and completing
one phantom scan per human scan in a clinical trial.
Dynamic Contrast-Enhanced MRI Perfusion Phantom
As part of the efforts of the RSNA QIBA, a phantom was
designed and produced that could be used to (i) assess
bias and variance of signal intensity measurements from
T1 mapping and dynamic contrast-enhanced (DCE) MRI
acquisitions across scanners, centers, and time; (ii) assess
the effects of parallel imaging and B1 corrections; (iii)
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form one component of a qualification process for imaging
centers enrolling in DCE-MRI clinical trials and for ongo-
ing quality control in such studies; and (iv) allow compar-
isons of T1 measurements and DCE-MRI data acquired on
different scanners and across time, and harmonization of
such measures (71). The phantom was critical to the
development and implementation of the QIBA DCE-MRI
profile (3), which addresses all aspects of a DCE-MRI
study, including data acquisition and processing. At the
time of development, there were no other phantoms avail-
able to assess the contrast response of acquisition sequen-
ces across the range of tissue and vascular R1 values
encountered during a DCE-MRI acquisition, particularly at
3 T, while also assessing the effects of nonuniform sensi-
tivity of phased array coils in abdominal imaging.
The RSNA QIBA DCE-MRI phantom (Fig. 1) is a multi-
compartment phantom consisting of a 36-cm-diameter,
15-cm-height cylindrical polycarbonate shell containing
a set of 32 3.0-cm spheres in a uniform fill solution (71).
The spheres are doped with NiCl2 to achieve T1 values
(Table 1) spanning the ranges expected in a vascular
input function (VIF) compartment (VIF spheres) and in
tissue (tissue spheres) during a typical DCE-MRI study.
To appropriately load the RF coil, the phantom is filled
with a 30-mM NaCl (Sigma-Aldrich, St. Louis, Missouri,
USA) solution in water. The phantom was used for site
qualification and requalification in the American College
of Radiology Imaging Network 6701 prostate DCE and
diffusion-weighted imaging clinical trial (72).
Diffusion Phantoms
Isotropic Diffusion Imaging
Isotropic diffusion imaging is used as a biomarker to
identify tumors and track response to treatments (14,15).
To have sufficient confidence in diffusion MRI measure-
ments, several research groups performed quality-
assurance testing with phantoms. Laubach et al. used a
sucrose solution to alter the apparent diffusion coeffi-
cient (ADC) of water molecules (73), whereas Tofts et al.
used alkanes to achieve a range of ADC values (74). Dela-
kis et al., using two aqueous test solutions of copper sul-
fate (CuSO4) and sucrose, developed a quality control
protocol to assess the accuracy, precision, and reproduc-
ibility of ADC measurement on a clinical MRI system
(65). Wang et al. developed an acetone and deuterium
oxide (D2O) phantom that demonstrated ADC values in
the physiologic range (0.57 – 3.16 3 103 mm2/s) at 0C
without any signal from the D2O solute (75).
The Cancer Research UK Clinical MR Group and Royal
Marsden Hospital uses the sucrose diffusivity phantom
(containing a solution with known water diffusivity) and
nondiffusivity phantom, which contains a highly vis-
cous, very large mono-disperse polymer with very low
ADC, for diffusion MRI experiments (76). The sucrose
FIG. 1. A diagram (a) and an image (b) of the QIBA DCE-MRI phantom. The inner set of eight spheres, referred to as the VIF spheres, is
distributed around a 14.0-cm-diameter circle. The remaining 24 spheres are uniformly distributed around a 29.0-cm-diameter circle, and
consist of three sets of eight “tissue spheres” spaced at 45 increments, with each set having an R1 range of 0.67 to 7.54 s
1. The low-
est R1 sphere in each set of eight was positioned at 0
, 105, and 210, respectively, to produce three virtual rotations of the three sets
of tissue spheres, to facilitate the investigation of spatial signal dependencies arising within phased-array coils without the need to
physically rotate the phantom between acquisitions.
Table 1
Theoretical Sphere R1 (¼1/T1) Values at 3 T and Corresponding
NiCl2 Concentration
VIF spheres Tissue spheres
Sphere R1 (s
1) [NiCl2] (mg/L) R1 (s
1) [NiCl2] (mg/L)
1 0.75 87.1 0.67 69.68
2 2.63 479.03 0.94 127.40
3 6.56 1302.09 1.33 209.03
4 11.56 2347.24 1.89 324.48
5 17.56 3601.42 2.67 487.74
6 24.56 5064.64 3.77 718.63
7 32.56 6736.88 5.33 1045.15
8 41.56 8618.16 7.54 1506.93
Note: The R1 values were chosen to mimic the range of values
typically encountered in a DCE-MRI study for both the VIF and tissue
compartments. To achieve these relaxation rates, the corresponding
concentrations of NiCl2 are provided, assuming a water-relaxation
rate of 0.33 s1 and NiCl2 relaxivity of 0.62 (mMs)1 at 3T.
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phantom allows detection of drift in the measured ADC
on the same MRI system over time, and how well ADC
values calculated from a single magnetic field gradient
agree across three orthogonal gradient directions. The
nondiffusivity phantom is used for testing eddy current–
induced image distortions.
Diffusion is a thermally driven process and is highly
sensitive to temperature variation; the ADC of pure water
changes approximately 3%/K near room temperature. To
obtain an accurate reference standard, an ADC phantom
must have accurately controlled or measured tempera-
ture. Padhani et al. recommended the use of ice water in
a phantom to eliminate thermal variability (18), leading
to the efforts of Chenevert et al. (77) and Malyarenko
et al. (78) to develop an ice water phantom (0C) to give
a stable water proton ADC of 1.1 3 103 mm2/s. With
this phantom, large errors in the ADC were observed
when measured off magnet isocenter, as a result of non-
linear gradients (78). Boss et al. (44) demonstrated an
improved isotropic diffusion phantom (Fig. 2), devel-
oped by the coordinated efforts of the National Cancer
Institute, RSNA QIBA, and the National Institute of
Standards and Technology, which incorporates a vari-
able ADC array using aqueous solutions of polyvinylpyr-
rolidone (PVP) (79). The phantom has a modular
polycarbonate shell that can be disassembled to fill the
phantom with an ice-water bath to accurately control tem-
perature. Users do find the temperature control of this
phantom challenging and would prefer to measure the
phantom temperature rather than set up an ice bath.
Additionally, the T1 and T2 values of the PVP material do
not span the full physiologic range at 0C: T1 ranges from
157 to 1450 ms, and T2 spans 126 to 1040 ms for the PVP
solutions at 1.5 T. At 0C, the ADC values of PVP do not
span the physiologic range; however, at higher tempera-
tures (e.g., 37C), the ADC values of PVP cover the full
range of isotropic diffusion in the human body.
Diffusion Tensor MR Imaging
Anisotropic diffusion imaging characterizes the path of
water molecule diffusion and is used to characterize
brain injury (16,17). Several different approaches were
used to mimic the anisotropic diffusion of water seen in
the brain (80–82). An acrylic water-filled phantom with
a grid structure was used to evaluate geometric distor-
tions in functional MRI and diffusion tensor imaging
(83). The phantom provided accurate geometric informa-
tion over the scanning volume for echo-planar imaging–
based functional MRI and diffusion tensor imaging of the
human brain. The results suggest this phantom can
reveal geometric distortions not easily detected by stan-
dard MRI phantoms. In another study, separate water
phantom calibration experiments were conducted to
accurately determine and correct eddy current–induced
image distortions for in vivo diffusion anisotropy (84).
Further investigations examined the practicalities of
using separate phantom calibration data to correct high
b-value diffusion tensor imaging measurements by inves-
tigating the stability of these distortion parameters, and
hence the eddy currents, with time (85). Rayon fibers
were used to mimic axonal bundles, crossing at 90 to
validate q-ball imaging (86). Fieremans et al. used high
molecular-weight polyethylene fibers, packed together
tightly in heat-shrink tubing, to compare the experimen-
tal diffusion-weighted MRI and NMR results with Monte
Carlo simulations of the apparent diffusion coefficient,
fractional anisotropy, and kurtosis (82). Anisotropic dif-
fusion and elastic properties of the brain were mimicked
with Spandex fibers in a polyvinylalcohol hydrogel to
simultaneously evaluate diffusion tensor imaging and
MR elastography in a single reference object (87). These
fiber phantoms generate a porous structure that mimics
the hindered space seen in axonal bundles; however,
they do not also mimic the restricted water space. Glass
capillaries have been used to simulate a restricted space
for water diffusion, allowing comparison of different
reconstruction techniques (88,89); these phantoms lack
the hindered water space and cannot easily create fiber
crossings. Hollow polypropylene fibers have been incor-
porated into a phantom, allowing for fiber crossing and
changes in packing density to create both a hindered and
restricted water space (90).
FIG. 2. Ice-water diffusion phantom (a) with an array of PVP solutions to obtain ADC values from 0.1 3 103 to 1.1 3 103 mm2/s at
0C (b). The phantom has a spherical geometry with an outer diameter of 194mm, designed to fit in existing multichannel head coils.
Thirteen high-density polyethylene vials (31.5 mm outer diameter and approximately 68mm tall) contain PVP solutions ranging from 0 to
50% PVP by mass fraction in water, arranged in two concentric circles, with a central vial filled with deionized water. These vials are in
one plane of the phantom; to characterize all three imaging planes, the phantom must be physically rotated.
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Flow Phantom
Phase-contrast MRI is used to assess hemodynamics in
cardiovascular blood flow for a range of clinical applica-
tions, such as assessment of pulmonary to systemic flow
shunting (91,92), measurement of peak velocity to assess
valvular disease (93,94), and the assessment of pressure
gradient through stenosis in arteries (95,96). In all cases,
guideline-driven quantitative thresholds exist to inform
the need for therapy or intervention. The use of
guideline-driven thresholds underlines a need for accu-
racy and repeatability to be assessed at a system level for
phase-contrast MRI blood-flow measurements.
Numerous efforts have constructed flow phantoms to
mimic vascular territories and disease conditions (97–99).
These single-site “in-house” studies have reported the
accuracy and precision of phase-contrast MRI to measure
case- and site-specific regional velocity, bulk flow rates
(velocity integrated over a region of interest), and net flow
(temporally and spatially integrated velocity). Computa-
tional fluid dynamics, particle image velocimetry, and
bulk flow transducers are typically used to validate the
phase-contrast MRI flow-field measurements. However,
no literature exists on a proven, robust, “dynamic fluid”
phantom that sufficiently addresses all challenges associ-
ated with creating a reliable and reproducible fluid flow
field for multisite use with proven test-retest stability.
To date, the most extensive studies have used static
tissue phantoms. Static tissue phantoms can be used to
study phase offset errors, an error postulated to have a
large effect on the accuracy of spatially and temporally
integrated phase-contrast flow measurements. The most
comprehensive multisite effort to investigate phase-offset
errors was undertaken by members of the European Soci-
ety of Cardiology Working Group. Concerned that back-
ground phase offsets were a cause of flow-measurement
inaccuracies in commercial MRI systems, the group
designed a 10-site, 3-manufacturer, 12-system study (all
1.5 T) (100). The phantoms consisted of 10- to 15-L tanks
of aqueous gelatin solution, which were doped with 5
mmol/L of gadolinium-diethylenetriamine pentaacetic
acid to facilitate the measurement of small background
phase offsets. Gelatin eliminated phase differences as a
result of convection and motion-induced fluid currents.
By assuming a worst-case error from spatial and temporal
integration, an offset of 0.6 cm/s was chosen as a quality
threshold (given the potential to cause a 10% error in a
pulmonary to systemic shunt measurement). Noting that
this was a worst-case scenario, 35 of the 36 uncorrected
exams (three experiments per scanner) were found to
exceed the quality threshold. A follow-up study in nine
1.5T scanners (involving three different manufacturers)
used the same phantoms to understand the correlation of
exam protocol parameters on phase-offset errors (101). No
generic protocol was found to generate acceptable offset
values across all scanners (using a 0.6-cm/s quality met-
ric). Both studies recommended post hoc corrections to
improve accuracy of the measurements, although no uni-
versally accepted algorithm was recommended. Multisite
temporal stability of background offsets was also exam-
ined with this phantom design (102).
Although significant efforts established the importance
of phase offsets with static phantoms, a need exists for a
robust, dynamic phantom to replicate spatially and tem-
porally varying velocities across a large range of magni-
tudes. In single-center, in-house studies, dynamic fluid
phantoms were used to replicate pulsatile flow (103), ste-
nosis geometries (104), and other patient-specific geome-
tries (105). The most comprehensive multisite effort to
date was initiated in 1999 by the Flow and Motion Study
Group of the International Society for Magnetic Reso-
nance in Medicine in the Assessment of Methodology of
Phase Mapping for Flow Measurement trial. A prelimi-
nary two-site report was published in 2005, which
detailed the design criteria and plans for a dynamic-flow
phantom capable of mimicking various vessels and FOV
configurations (106). However, there were no spatially
and/or temporally resolved flow measurements with this
flow phantom. The design of a robust dynamic fluid-
filled phantom is challenging to implement across multi-
ple sites for a multitude of reasons. Without significant
effort (and cost), pump systems and control hardware
must reside outside of the scan room (as a result of elec-
tromagnetic noise and ferromagnetic components). This
means fluid tubing must be routed through waveguides
to the control room, and plumbing connections must be
repeatedly disassembled and reassembled, thereby risk-
ing joint failure, introduction of air bubbles, or cata-
strophic leakage in the scan room. Furthermore, the inlet
conditions, position, and configuration of the assembly
(e.g., head height and tubing length, compliance, resis-
tance) will vary according to waveguide location and
exam room layout. For these reasons, a dynamic fluid-
filled phantom may suffer in terms of reliability and
repeatability. The most promising alternative is a rotating
gelatin disk phantom, whereby a large range of known
velocities can be measured using a priori knowledge of
the angular rotation and measurement position in rela-
tion to the axis of rotation. Challenges associated with
fluid motion, leakage, and presence of air bubbles are
mitigated. A few studies reported the use of such phan-
toms to test velocity and phase-contrast measurement
methods (107–109). This configuration compromises the
ability to evaluate the effects associated with fluid flow
in vessels and boundary interactions, including partial
volume artifacts or the presence of turbulence, with
robustness and cost effectiveness.
Breast Phantom
Breast MRI with quantitative methods is increasingly
used for breast cancer diagnosis, staging, and monitoring.
For these quantitative applications, it is important to
understand and mitigate the sources of variability, such
as fat suppression, variations in the left and right sides
of the coil, and B0 inhomogeneity across the large image
volume. To address these issues, breast phantoms have
been created for quality control (110), well-mixed fat and
fibroglandular tissue (111), and DCE-MRI in the breast
(112).
The University of California San Francisco and
National Institute of Standards and Technology breast
phantom design with flexible outer shell easily fits into
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different coils and is useful for clinical breast imaging
techniques (43,113). The phantom was tested using the
sequences of a particular breast imaging clinical trial.
The fibroglandular mimic exhibited target T1 values of
1300 to 1400 ms and 1500 to 1850 ms on 1.5 T and 3 T
clinical systems, respectively. Fat was suppressed using
standard techniques, and PVP solutions mimicked the
range of ADC values from malignant tumors to normal
breast tissue (43). The phantom does not include any
dynamic components for DCE-MRI as other designs have
(112). Additionally, the T1 and T2 values of the PVP are
not physiologic for breast fibroglandular or tumor tissue.
One challenge of the two-phantom design is it requires
twice the scan time to assess both sides of the coil. It is
important to assess both sides of the coil, as one study
found geometric distortion between the right and left
coil sides of multiple platforms when using echo-planar
imaging diffusion techniques (113). A chest cavity model
may need to be added to properly replicate the B1 homo-
geneity challenges in breast imaging.
Proton-Density Fat Fraction Phantom
Quantification of fat in the body has many important
applications in the liver, heart, and pancreas, as well as
in skeletal muscle. Proton-density fat fraction (PDFF) is
currently regarded as the most practical and meaningful
MR-based biomarker of tissue fat concentration (114).
The PDFF represents the ratio of MR-visible fat protons
to the total number of MR-visible water and fat protons.
The PDFF phantoms have been used to analyze the
accuracy of MR-based PDFF techniques for liver fat
quantification (Fig. 3) (115). This phantom consists of
separate vials with approximately 40-mL volume for
each, and a different PDFF, typically in the range of 0 to
50% to reflect clinically relevant liver fat fractions. The
vials store a gel mixture of peanut oil and deionized
water, together with minute concentrations of additional
substances to ensure mixture of the oil and water and to
prevent spoiling. The PDFF phantoms have also been
used to assess the accuracy and reproducibility of PDFF
measurements across different sites, vendors, and field
strengths (116,117).
A further development to a PDFF phantom includes
the need for it to reflect physiologically relevant relaxa-
tion (i.e., R2) rates. It is important that the R

2 values for
both the fat component and water component remain
similar to one another, which has been measured in vivo
(118,119).
IMPLEMENTATION OF QUANTITATIVE MRI
For quantitative MRI to be widely adopted, a framework
is required to ensure that the quantitative measures are
comparable over time, between subjects, between scan-
ner sites, and between manufacturers. The proposed sys-
tem phantom and application-specific phantoms are one
part of the framework, along with standardized protocols
and data collection. With an established framework,
quantitative MRI can be used to assess outcomes in clini-
cal trials and for clinical diagnostics. In particular, clini-
cal trials and clinical use of quantitative MRI can benefit
from the use of a phantom in many ways, including proto-
col development, selection of RF coils, training of technol-
ogists, quality-control standards, standardized analysis,
and correction of collected images, if necessary.
This paper discusses the design process, requirements,
and recommendations for a phantom to assess the perfor-
mance and stability of an MRI system. In addition, we
reviewed application-specific phantoms that are designed
to evaluate the performance of a particular technique. In
this final section, we discuss the implementation of quan-
titative MRI.
Magnetic Resonance Imaging System Constancy
System constancy data should be tracked regularly at all
MRI systems and especially those doing quantitative
measurements. The described system phantom enables
assessment of scanner performance over time (stability or
constancy) for many parameters. For example, the system
phantom can be used to track B1 and B0 nonuniformity,
geometric nonlinearity, gradient amplitude, image uni-
formity, SNR, transmitter and receiver gain, receiver
bandwidth, image ghosting, and eddy currents, using the
methods described in International Electrotechnical
Commission 62464-1 (49). For any stability parameter,
prospective criteria should be developed to generate a
FIG. 3. a: Vial consisting of a PDFF mimic. b: Multiple vials can be scanned simultaneously by placing them in a phantom holder that is
filled with deionized water (128). c: The PDFF for each of the vials can be estimated using MRI. In this example, the PDFF values are
(beginning at 12 o’clock position and moving counterclockwise) 0, 5, 10, 15, 20, 30, 40, and 50%.
56 Keenan et al.
service call for “out of specification” results. Friedman
and Glover present the advantages of a quality-control
standard for evaluation and acceptance of a new scanner,
benchmarks for comparisons with other MRI centers,
monitoring system constancy through hardware and soft-
ware upgrades, and planning of multicenter studies (45).
Standard Protocols
A clinical trial requires protocol standardization across
participating sites to ensure that conclusions can be
drawn from the data. The challenge is to minimize dif-
ferences in effective acquisition parameters across sites
for multicenter studies and across time for multicenter
and single-center studies. This is confounded by varying
hardware and software configurations within and across
manufacturers’ platforms. The implication for protocol
standardization is that the actual scan protocol may be
slightly different across manufacturers to get the same
contrast-to-noise ratio required by the analytical
technique.
One approach uses the strategy of ensuring that spe-
cific pulse-sequence parameters are identical, to the
degree possible. The advantage of this approach is that it
is easy to implement. The disadvantage is that subtle
variations in implementation, which are not always
known outside of the manufacturer, can cause significant
changes in image appearance (e.g., contrast, artifact prop-
agation). Further complications exist even within the
manufacturers’ platforms over time. Nevertheless, this
should be a starting point for protocol definition and
standardization.
Clinical use of quantitative MRI requires harmoniza-
tion, and these efforts are led in part by RSNA QIBA.
Clinical trials can build on the work of QIBA to create
standard protocols for each technique. The QIBA profiles
provide claim statements for quantitative imaging bio-
markers within a specified clinical context. These claim
statements indicate the reproducibility of the quantita-
tive measurement as determined by existing literature
and biomarker-specific groundwork projects. The QIBA
profiles provide a list of requisite activities and associ-
ated actors to meet the claim statements, as well as
assessment procedures to ensure proper quality assur-
ance. These activities can include subject selection and
preparation, image acquisition and reconstruction, analy-
sis, and interpretation. Profiles undergo a strict vetting
procedure within QIBA, and then pass through the
stages of public comment, consensus, technical confir-
mation, claim confirmation, and clinical confirmation, as
the profile is adopted and thoroughly tested in the clini-
cal environment. Physical phantoms and virtual phan-
toms (digital reference objects) are essential in QIBA
profiles.
An appropriate phantom can be used to refine the
“identical” protocols, such that the images obtained
across platforms are equivalent. This process includes
removing any postprocessing steps, which may not be
readily apparent to the user. Once a standard protocol is
established, all protocols should be provided in an elec-
tronic fashion to the sites, if possible, to minimize entry
errors at the console. Each site should provide images of
an appropriate phantom from the standard protocol as a
qualification step to be included in a clinical trial.
Standardized Training of Technologists
The “gatekeeper” for image quality is the local technolo-
gist (radiographer, technician). It is recommended that
uniform training be provided for all sites and that such
training consider variations in hardware and software
platforms. Such training can be accomplished at a group
meeting, individual training visits to the site, and/or by
video instructions that provide specific details of the
study (e.g., positioning criteria). The phantom should be
used to provide hands-on training, and the phantom
images will allow the coordinating center to determine
whether a site is ready to be included in a clinical trial.
Specific Image Analysis Procedures
A well-designed phantom is useful for developing analy-
sis methods, evaluating how system-to-system error
affects results, and correction of images for uniform anal-
ysis/error reduction.
Large-scale clinical studies of MR images often require
the application of quantitative image analysis methods
on data sets that were acquired by multiple sites. How-
ever, such methods are often developed on data sets
from a single MR system vendor and/or scanner model.
To evaluate the variability across different MRI systems,
the methods should be tested and validated on data sets
from multiple scanners with different properties using
the same standard protocols.
All metadata (e.g., header information) received from
clinical trial sites should be checked for protocol adher-
ence. At the beginning of the study, acceptable devia-
tions should be determined (ideally by evaluation of
such deviations on the analytical procedure), and the
ranges documented in the project manual(s). If a hard-
ware or software upgrade generates parameters outside
of the prospective criteria, the effect on analysis should
be determined and decision made about whether to drop
the site or accept the protocol deviation. If the deviation
is acceptable, the initial range perhaps should have been
broader. Ideally, all such parameter restrictions should
be prospectively determined and based on the actual out-
come measure. When feasible, “electronic protocols”
should be centrally distributed to avoid errors associated
with users translating information from written protocols
into scanners.
For example, Chenevert et al. used an ice-water phan-
tom to compare measurement of ADC across systems,
including multiple manufacturers and platforms (120).
The images generated by one of the scanners appeared to
have image intensity scaling that was not accounted for
by most quantitative image analysis tools. Incorrect
image scaling leads to measurement bias, and the scaling
of images must be accounted for in the image analysis
routine.
Future Implications
The use of MR-based measurements as biomarkers is a
driver for developing a framework for quantitative MRI
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adoption, and clinical applications will also benefit con-
siderably from these developments. Of interest, a decade
ago, quantitative imaging was seen as the future by the
leaders of the radiology community, as reflected by the
statement “the RSNA remains committed to helping to
transform Radiology from a qualitative to quantitative
science” (121). With the advent of methods such as mag-
netic resonance fingerprinting (122) and compressed
sensing (123,124), quantitative MRI can now be per-
formed in a clinically appropriate timeline; however,
quality control with a quantitative MRI phantom is nec-
essary to ensure the accuracy and precision of results.
Such sequences and corresponding reconstruction meth-
ods develop behavior that significantly differs from that
of “classic” MRI methods, and a system phantom can
provide a way to rigorously characterize the behavior of
these methods when standard image quality metrics like
SNR are no longer valid. Looking forward, a comprehen-
sive system phantom along with MR imaging acquisition
(i.e., pulse sequence), reconstruction, and analysis soft-
ware and quality assurance recommendations could be
an accreditation program for quantitative MRI, similar to
the ACR MR Accreditation Program currently in place
for qualitative MRI.
CONCLUSIONS
Quantitative MRI enables noninvasive measurements of
biomarkers pertinent to clinical trials and diagnostic
tests. This paper, prepared by the International Society
for Magnetic Resonance in Medicine, Ad Hoc committe
on Standards for Quantitative Magnetic Resonance,
describes the need for phantoms, previous standardiza-
tion attempts, an overview of available phantoms, and
the desired features of a system phantom for quantitative
MRI. The system phantom is designed to be used for
quality control (assessing system constancy) and with
the intentions of comparing results across manufacturer
systems, hardware and software, across time, and across
physiologic ranges at 1.5 T and 3 T. The system phantom
prototype was constructed (125) and later commercial-
ized; both the prototype and commercial phantoms were
used by the International Society for Magnetic Reso-
nance in Medicine Ad Hoc committee on Standards for
Quantitative Magnetic Resonance for studies of T1 varia-
tion (126,127). The full manuscript describing the system
phantom is in preparation. The improved accuracy and
reproducibility of quantitative results through use of a
system phantom should increase statistical power,
patient safety, and efficacy and efficiency of clinical tri-
als, and is a critical step toward the full potential of MR
biomarkers.
Any quantitative MRI phantom data need to be easy to
analyze, to enable adoption by many different scanner
locations and users. This is true both of a general system
phantom and application-specific phantoms. It is there-
fore important that any phantom designed to characterize
MRI performance meet certain requirements to be amena-
ble for quantitative analysis. To allow regular quality
control, a technologist should be able to position and
image the phantom and import the images to the soft-
ware package, and the analysis software should generate
a report with the system status. Another benefit of the
system phantom is that it can be used for comparative
studies of processing strategies, such as those available
from vendors or research groups for quantitative MRI sig-
nal models.
In this paper, we reviewed the application-specific
phantoms developed for certain quantitative MRI techni-
ques. Additional application-specific phantoms are still
needed, such as for musculoskeletal techniques and the
combination of MRI and positron emission tomography.
The components and materials research for the system
phantom can be used to develop application-specific phan-
toms, especially given the proposed modular structure.
MRI system stability is required for implementation of
quantitative MRI, especially to enable biomarkers for
diagnostic use. A standardized MR system phantom will
support the efforts of the quantitative MRI community,
including RSNA QIBA and the National Cancer Insti-
tute’s Quantitative Imaging Network. Research develop-
ments will be enabled by the system phantom, such as
acquisition and modeling for relaxometry. A standard
system phantom, with SI-traceable components that will
be monitored for long-term stability by a national metrol-
ogy institute, will further facilitate the use of MRI meas-
urements as a biomarker. Most importantly, to support
clinical use of quantitative MRI, such a phantom must
be adopted by the user community and equipment man-
ufacturers for regular use.
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Fig. S1. American College of Radiology large phantom (images courtesy of
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